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Abstract
Aims/hypothesis We aimed to describe the prevalence of
retinopathy in an aged cohort of Icelanders with and
without diabetes mellitus.
Methods The study population consisted of 4,994 persons
aged ≥67 years, who participated in the Age, Gene/Environ-
ment Susceptibility—Reykjavik Study (AGES-R). Type 2
diabetes mellitus was defined as HbA1c ≥6.5% (>48 mmol/
mol). Retinopathy was assessed by grading fundus photo-
graphs using the modified Airlie House adaptation of the
Early Treatment Diabetic Retinopathy Study protocol. Asso-
ciations between retinopathy and risk factors were estimated
using odds ratios obtained from multivariate analyses.
Results The overall prevalence of retinopathy in AGES-R
was 12.4%. Diabetes mellitus was present in 516 persons
(10.3%), for 512 of whom gradable fundus photos were
available, including 138 persons (27.0%, 95% CI 23.2, 31.0)
with any retinopathy. Five persons (1.0%, 95% CI 0.3, 2.3)
had proliferative retinopathy. Clinically significant macular
oedema was present in five persons (1.0%, 95% CI 0.3, 2.3).
Independent risk factors for retinopathy in diabetic patients in
a multivariate model included HbA1c, insulin use and use of
oral hypoglycaemic agents, the last two being indicators of
longer disease duration. In 4478 participants without diabetes
mellitus, gradable fundus photos were available for 4,453
participants, with retinopathy present in 476 (10.7%, 95% CI
9.8, 11.6) and clinically significant macular oedema in three
persons. Independent risk factors included increasing age and
microalbuminuria.
Conclusions/interpretation Over three-quarters (78%) of
retinopathy cases were found in persons without diabetes
and a strong association between microalbuminuria and
non-diabetic retinopathy was found. These results may have
implications for patient management of the aged.
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Introduction
The global burden of diabetes is increasing and trends in
fasting plasma glucose have been on the rise since 1980 [1].
The number of people with diabetes in the world is
expected to double between 2000 and 2030 [2]. According
to the WHO, an estimated 5% of global blindness is due to
diabetic retinopathy (DR) [3]. Retinopathy in persons
without diabetes, sometimes mistakenly referred to as DR,
is estimated to occur in up to 15% of the general
population, this prevalence being attributed to older age
and systemic hypertension [4–6].
The experience in Iceland parallels that observed
globally. The prevalence of type 2 diabetes mellitus in
middle-aged men in Iceland doubled from 1967 to 2002,
coinciding with the increasing BMI in the population [7]. In
a national diabetic eye screening programme, the preva-
lence of DR among Icelandic type 2 diabetic patients was
reported in 1994 to be 41% [8]. Of those in this screening
programme and without retinopathy at baseline, only 1% of
patients with type 2 diabetes developed proliferative
retinopathy over a 10 year observation period [9]. In a
recent study, we reported that the overall prevalence of
visual impairment in Icelanders aged 50 years and older
was 1% according to WHO criteria (visual acuity <6/18 in
the better eye) [10]. No participant had bilateral visual
acuity less than 6/12 due to diabetic eye disease, and only
one became visually impaired due to DR over a 5 year
period [11].
Here, data from the Age, Gene/Environment Suscep-
tibility—Reykjavik Study (AGES-R) [12] are used to
provide population-based estimates of the prevalence and
severity of retinopathy and associated factors among
elderly Icelanders with and without diabetes mellitus.
Methods
Study details The AGES-R study is an epidemiological,
population-based study aimed at investigating genetic and
environmental factors contributing to disease as well as to
healthy ageing [12]. The study originates from the
Reykjavik study, which was conducted by the Icelandic
Heart Association (IHA) between 1967 and 1997 [12–14].
Participants of that study were men and women who were
born between 1907 and 1935, and were randomly sampled
and living in the Reykjavik area in 1967. At the time of
recruitment into AGES-R, 11,549 persons participating in
the original Reykjavik Study (38%) were still alive, and a
random sample of 5,764 survivors was enrolled. The
AGES-R examinations took place from February 2002 to
February 2006 [12–14]. The comprehensive AGES-R
examination protocol required each participant to complete
three visits to the IHA Research Center over a period of 3
to 6 months. During the assessment at the IHA Research
Center (see below), participants completed a detailed
interview including questions about diabetes, eye health
and cardiovascular history. Blood specimens were drawn
and an extensive medical examination, including an eye
examination, was performed as described below. Transport
to the IHA Clinic was provided for those who asked for it.
Participants were asked to bring all medications that they
had used in the previous 2 weeks. The AGES-R study
methods, examination protocol and characteristics of the
cohort have been described in detail elsewhere [12–14].
Informed consent was obtained from all participants. The
study was approved by the National Bioethics Committee
in Iceland, which acts as the Institutional Review Board for
the IHA (VSN-00-063), and by the National Institute on
Aging Intramural Institutional Review Board.
Definition of diabetes mellitus and laboratory tests The
criteria used for type 2 diabetes diagnosis were self-
reported diabetes in the questionnaire, and/or use of
diabetes medication or HbA1c ≥6.5% (≥48 mmol/mol).
The latter is a recently recommended approach and cut
point for diagnosis of diabetes, and is intended to better
avoid the problem of day-to-day variability of glucose
values [15]. To be able to compare our results with results
from earlier publications, we also, in a separate analysis,
used fasting serum glucose of ≥7 mmol/l for undiagnosed
diabetes mellitus, based on earlier WHO recommendations
[16, 17]. These last results are briefly mentioned in the text.
The criteria for type 1 diabetes included age ≤25 years at
diagnosis and insulin dependence.
Blood samples were drawn after overnight fasting. Total
cholesterol, HDL-cholesterol, triacylglycerol, high-
sensitivity C-reactive protein, serum glucose and HbA1c
were analysed on an Hitachi 912 analyser (Mito, Japan)
using reagents from Roche Diagnostics (Mannheim, Ger-
many) and following the manufacturer’s instructions. LDL-
cholesterol was calculated using the Friedewald equation
[18, 19]. The coefficient of variation (%) was: for serum
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glucose 1.8, for total cholesterol 1.4, for HDL 2.3 and for
urinary albumin 4.8.
Eye examination The visual acuity of each eye was
measured using an auto-refractokeratometer (ARK-760A;
Nidek, Tokyo, Japan) with a built-in Snellen chart. Pupils
were then dilated with tropicamide eye drops 10 mg/ml and
photographs of the retina taken. For each eye, two 45-
degree digital retinal images, centred on the optic disc (field
1) and the macula (field 2), respectively, were taken using a
CR6 non-mydriatic camera (Canon, Tokyo, Japan) with a
Canon D60 camera back. Images were evaluated at the
Ocular Epidemiology Reading Center, University of Wis-
consin using the modified Airlie House Classification
system [20]. EyeQ Lite image processing software was
used [21]. All graders were masked to the health status of
participants.
Definition of retinopathy and macular oedema If the grader
was at least 90% certain that a retinopathy lesion was
present, the lesion was marked as definite. The grader then
assigned a retinopathy level according to the Modified
Airlie House adaptation from the Early Treatment Diabetic
Retinopathy Study protocol [20]. The following grading
criteria were used: no DR (levels 10–13), mild non-
proliferative DR (NPDR) (levels 14–20), moderate to
severe NPDR (levels 41–51) or proliferative DR (PDR)
(levels 60–80). Macular oedema was defined by hard
exudates in the presence of microaneurysm and blot
haemorrhage within 1 disc diameter from the foveal centre,
or if focal or macular grid photocoagulation scars were
present in the macula. Clinically significant macular
oedema (CSMO) was considered present when oedema
involved the fovea or was within 500 μm of the fovea, or if
photocoagulation scars were present in the macula.
Assessment of factors associated with retinopathy The
duration of diabetes was calculated as the difference
between reported age of diabetes diagnosis from the
interview and the year of the AGES-R examination. Use
of medications was noted from medications brought to the
clinic and from self-report questionnaire. Blood pressure
was assigned using the mean value of two blood pressure
measurements with a large-cuff mercury sphygmomanom-
eter. Hypertension was defined by self-reported doctor’s
diagnosis of hypertension, use of hypertensive medication,
or measured systolic blood pressure ≥140 mmHg or
diastolic blood pressure ≥90 mmHg. BMI was calculated
from measured height and weight (kg/m2). Microalbumi-
nuria was noted as present if the albumin/creatinine ratio in
a random urine sample was >300 mg/g. GFR (ml min−1
1.73 m−2) was estimated using the Modification of Diet in
Renal Disease (MDRD) formula [22].
HbA1c was imputed for 7% of the participants with
missing data by applying the expectation-maximisation
(EM) algorithm in the statistical program PROC MI
(SAS/STAT Institute, Cary, NC, USA). The imputation
was performed separately for participants without and those
with diabetes, depending on medication use, and using age,
fasting serum glucose and duration of diabetes as the
predictors for HbA1c. Neither diabetes status nor retinopa-
thy status was associated with missing HbA1c. HbA1c was
imputed for five persons with undiagnosed diabetes
mellitus. However, their fasting serum glucose was
8.9 mmol/l or higher.
Data handling and statistical analysis For statistical anal-
ysis we used SAS Enterprise Guide software, version 9.1
(SAS Institute, Cary, NC, USA). Analysis of eyes was
based on the participant’s eye with the most severe
retinopathy lesion (worse eye). If images from an eye were
ungradable or if fundus photographs were unavailable,
scores from the contralateral gradable eye were used. The
overall prevalence of retinopathy was calculated using the
entire sample with information on retinopathy in at least
one eye.
Differences between groups were tested using χ2 test
for categorical variables and t test for continuous
variables. Confidence intervals for ratios were calculated
using binominal distribution. Logistic regression models
adjusting for age and sex were run for each risk factor. In
the multivariate models, we included age, sex, systolic
blood pressure, hypertension as a categorical variable,
HbA1c and microalbuminuria; and, for participants with
diabetes, duration of diabetes and use of glucose-lowering
medication.
Results
Study cohort Of the 5,764 AGES-R participants, 4,994
completed an eye examination. Of these, 4,965 had
gradable photographs for at least one eye, as well as
clinical examination findings, along with blood and urine
test results. A comparison of participants and non-
participants is reported elsewhere [12]. Of the 4,994
participants, 516 (10.3%) fulfilled the criteria for diagnosis
of diabetes mellitus. Two persons (both women) were
younger than 25 years at diabetes diagnosis and insulin-
dependent. These two were therefore classified as having
type 1 diabetes mellitus, but were included in the analysis.
If we had classified by onset of diabetes mellitus <35 years
and insulin dependence, three more persons would also
have been classified as having type 1 diabetes mellitus.
Characteristics of participants by diabetes status are
presented in Table 1. Men were significantly more likely
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than women to have diabetes mellitus. Persons with
diabetes were more likely than those without to have
hypertension, larger BMI, higher fasting serum glucose,
lower total cholesterol, GFR <60 ml min–1 1.73 m–2, a
positive history of cardiovascular disease, higher levels of
HbA1c and microalbuminuria. The 83 participants with
undiagnosed diabetes mellitus had a mean age of
76.3 years.
Prevalence and factors associated with retinopathy in
participants with diabetes mellitus Gradable fundus photo-
graphs from at least one eye were available from 512 of the
516 persons with diabetes mellitus. Any DR was present in
one or both eyes in 138 persons (27.0%). Table 2 shows the
prevalence of DR and macular oedema by age, sex,
categories of diabetes duration and diabetes treatment.
Among those with diabetes mellitus, there were no
Table 2 Prevalence and severity of retinopathy and macular oedema in persons with diabetes mellitus
Group Any retinopathy Retinopathy Macular oedema
NPDR Any CSMO
Mild Moderate PDR
Persons with DM (n=512) n 138 120 13 5 9 5
% 27.0 23.4 2.5 1.0 18 1.0
95% CI 23.2, 31.0 19.8, 27.4 1.4, 4.3 0.3, 2.3 0.8, 3.3 0.3, 2.3
Age group (years)
67–74 (n=190) n 52 45 4 3 3 2
% 27.7 23.7 2.1 1.6 1.6 1.1
95% CI 21.2, 34.3 17.8, 30.4 0.6, 5.3 0.3, 4.5 0.3, 4.5 0.1, 3.7
≥75 (n=322) n 86 75 9 2 6 3
% 26.7 23.3 2.8 0.6 1.9 0.9
95% CI 22.0, 31.9 18.8, 28.3 1.3, 5.2 0.1, 2.2 0.7, 4.0 0.2, 2.7
Sex
Male (n=272) n 78 74 8 1 4 1
% 28.7 26.4 2.9 0.4 1.5 0.4
95% CI 23.4, 34.4 20.3, 31.0 1.3, 5.7 0.0, 2.0 0.4, 3.7 0.0, 2.0
Female (n=240) n 60 51 5 4 5 4
% 25.0 21.3 2.1 1.7 2.1 1.7
95% CI 19.8, 31.0 16.3, 27.0 0.7, 4.8 0.5, 4.2 0.7, 4.8 0.5, 4.2
DM
Undiagnosed (n=82) n 9 8 1 0 0 0
% 11.0 9.8 1.2 0 0 0
95% CI 5.1, 19.8 4.3, 18.3 0.0, 6.6 0.0, 4.4 0.0, 4.4 0.0, 4.4
Previously known (n=430) n 129 112 12 5 9 5
% 30.0 26.1 2.8 1.2 2.1 1.2
95% CI 25.7, 34.6 22.0, 30.5 1.5, 4.8 0.4, 2.7 1.0, 3.9 0.4, 2.7
Treatment
Insulin ± orala (n=37) n 24 14 7 3 4 2
% 64.9 37.8 18.9 8.1 10.8 5.4
95% CI 47.5, 79.8 22.5, 55.2 8.5, 35.2 1.7, 21.9 3.0, 25.4 0.7, 18.2
Only orala (n=270) n 82 76 4 2 4 3
% 30.4 28.1 1.5 0.7 1.5 1.1
95% CI 24.9, 36.2 22.9, 33.9 0.4, 3.8 0.1, 2.7 0.4, 3.7 0.2, 3.2
Diet or no treatment (n=205) n 32 30 2 0 1 0
% 15.6 14.6 1.0 0 0.5 0
95% CI 10.9, 21.3 10.1, 20.2 0.1, 3.5 0.0, 1.8 0.0, 2.7 0.0, 1.8
DM, diabetes mellitus
a Oral hypoglycaemic agents
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statistically significant age- or sex-specific differences in
the prevalence of any DR measure. Of the 83 persons with
undiagnosed type 2 diabetes mellitus, one did not have
readable fundus photographs and nine (11.0%) had any
retinopathy (eight mild, one moderate NPDR). The preva-
lence of any DR and CSMO was higher in those who were
being treated with insulin than in persons receiving other
forms of treatment. Their mean duration of diabetes was
24.9 (SD 13.7) years, compared with 11.1 (SD 9.7) years
for participants receiving oral treatment only and 6.8 (SD
10.4) years for participants without medical treatment.
Persons with any DR were younger at the time of diabetes
mellitus diagnosis (mean age 61.1 [SD 14.4] vs 66.3 [SD
11.6] years) and had longer duration of diabetes mellitus, i.e.
mean 13.7 (SD 12.6) vs mean 9.1 (SD 10.5)years.
In the multivariate analysis of participants with diabetes
mellitus (Table 3), we found HbA1c, insulin use and use of
oral hypoglycaemic agents to be associated with increased
risk of any retinopathy. Systolic blood pressure was
associated with increased risk of retinopathy in the
multivariate model. However, the categorical variable for
hypertension was not associated with increased risk of
retinopathy. As shown above, duration of diabetes mellitus
was highly confounded with type of treatment; in other
words, the use of insulin or oral hypoglycaemic agents was
an indicator of longer duration of diabetes mellitus. The
duration variable was therefore included in the multivariate
model, even though the p value (p=0.0645) did not reach
statistical significance. When the multivariate analysis was
limited to persons with diabetes of duration more than
10 years, however, the association with the use of insulin or
oral hypoglycaemic agents was of similar magnitude and
statistically significant. We found HbA1c to be significantly
associated with retinopathy if fasting glucose was left out of
the model. Additionally, the fasting glucose level was found
to be significantly associated with retinopathy when
selected before HbA1c, but after adjustment for diabetes
duration and medication use. Both variables could not be
retained in the model due to co-linearity; the correlation
between fasting glucose and HbA1c in participants with
diabetes was 0.73. The final variables in the multivariate
model were: age, sex, duration of diabetes mellitus, insulin
use, oral hypoglycaemic agent use, systolic blood pressure
and HbA1c.
Prevalence and factors associated with retinopathy in non-
diabetic participants Of the 4,478 non-diabetic persons in
the sample, 4,453 had gradable fundus photographs. Of
Table 3 Univariate and multivariate logistic regression results on risk factors for any retinopathy in persons with and without diabetes mellitus
Logistic regression n With diabetes mellitusa Without diabetes mellitusb
OR (95% CI) p value OR (95% CI) p value
Multivariate
Age, per 10 years 0.86 (0.57, 1.31) 0.4687 1.30 (1.09, 1.55) 0.0036
Sex, male vs female 0.96 (0.62, 1.51) 0.871 0.97 (0.79, 1.18) 0.7245
Systolic BP, per 10 mmHg 1.16 (1.04, 1.29) 0.0095 1.05 (1.00, 1.10) 0.0699
Duration per 10 years 1.21 (0.99, 1.48) 0.0645
Insulin use, yes vs no 3.51 (1.59, 7.77) 0.002
Oral hypoglycaemic, yes vs no 1.93 (1.21, 3.07) 0.0056
HbA1c per percentage point 1.35 (1.08, 1.68) 0.0078 0.93 (0.68, 1.27) 0.6431
Hypertension 1.23 (0.53, 2.86) 0.6235 1.01 (0.76, 1.33) 0.9665
Microalbuminuria, yes vs no 1.48 (0.88, 2.48) 0.1356 1.77 (1.30, 2.40) 0.0003
Univariate, adjusted for age and sex
Age, per 10 years 512 0.89 (0.61, 1.28) 0.5175 4,453 1.38 (1.16, 1.63) 0.0002
Sex, male vs female 512 1.21 (0.81, 1.79) 0.3498 4,453 1.01 (0.83, 1.22) 0.9216
Systolic BP, per 10 mmHg 512 1.18 (1.07, 1.29) 0.001 4,452 1.06 (1.01, 1.11) 0.0128
Duration per 10 years 498 1.41 (1.20, 1.66) <0.0001
Insulin use, yes vs no 512 5.79 (2.85, 11.76) <0.0001
Oral hypoglycaemic, yes vs no 512 2.15 (1.40, 3.29) 0.0004
HbA1c per percentage point 512 1.42 (1.19, 1.68) 0.0005 4,453 0.94 (0.69, 1.27) 0.6699
Hypertension 512 1.52 (0.74, 3.14) 0.2592 4,453 1.12 (0.87, 1.43) 0.3923
Microalbuminuria, yes vs no 506 1.97 (1.22, 3.17) 0.0056 4,403 1.82 (1.34, 2.47) 0.0001
a n=496 for multivariant analysis, n=512 for univariant analysis
b n=4,402 for multivariant analysis, n=4,453 for univariant analysis
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these, retinopathy was found in 476 persons (10.7%), as
shown in Table 4. Macular oedema was present in five
persons (0.1%), all of whom had branch retinal vein
occlusion. There was no sex-specific difference in the
prevalence of retinopathy among non-diabetic persons.
Factors associated with any retinopathy in a multivariate
model were older age and microalbuminuria (p=0.0003)
(Table 3). Higher systolic blood pressure was significantly
associated with retinopathy in the age- and sex-adjusted
model, but its significance was only marginal in the
multivariate model.
Discussion
This large population-based study of old persons reports an
overall prevalence of retinopathy of 12.4%. The prevalence
of DR was 27.0% and the prevalence of retinopathy in non-
diabetic participants was 10.7%. We used the recently
recommended and presumably more accurate HbA1c ≥6.5%
(≥48 mmol/mol) for diagnosis of diabetes. This classifica-
tion is expected to be better at capturing chronic hyper-
glycaemia than the older classification using fasting glucose
≥7 mmol/l [15]. Persons with diabetes mellitus are 2.5
times more likely to have retinopathy than non-diabetic
participants of comparable age, but over 75% of retinopathy
cases in our study occurred in persons without diabetes.
HbA1c, duration of diabetes mellitus, use of insulin and use
of oral hypoglycaemic agents were associated with
increased risk of retinopathy in persons with diabetes in a
multivariate model. Use of insulin and hypoglycaemic
agents was also associated with longer duration of diabetes
in a multivariate model. In persons without diabetes,
increased risk of retinopathy was associated with advancing
age and microalbuminuria. Microalbuminuria data show a
sort of dose–response, with a prevalence of 7.4% in those
with no diabetes mellitus, 12.0% in those undiagnosed and
21.3% in those with previously diagnosed diabetes mellitus
and mean disease duration of 12.4 years. These results
support the hypothesis that microalbuminuria may be a
marker of microvascular dysfunction. Studies of DR have
until recently used fasting blood glucose (7 mmol/l) to
diagnose diabetes mellitus. To facilitate comparison with
previous work, we additionally did uni- and multivariate
analysis using this definition, which is based on a one-time
event, in contrast to our present classification of type 2
diabetes mellitus (HbA1c), which is expected to capture
cases with chronic hyperglycaemia. Using the new classi-
fication, the group of participants with undiagnosed type 2
diabetes mellitus included only 50% of the number of
persons classified, based on fasting serum glucose. In
general, results were similar using the two classifications.
Table 4 Prevalence and severity of retinopathy and macular oedema in persons without diabetes mellitus
Group Any retinopathy Retinopathy Macular oedema
NPDR Any CSMO
Mild Moderate PDR
Persons without DM (n=4,453) n 476 472 4 0 5 3
% 10.7 10.6 0.1 0 0.1 0.1
95% CI 9.8, 11.6 9.7, 11.5 0.0, 0.2 0.0, 0.1 0.0, 0.3 0.0, 0.2
Age group (years)
67–74 (n=1,828) n 169 167 2 0 3 2
% 9.2 9.1 0.1 0 0.2 0.1
95% CI 8.0, 10.7 7.9, 10.6 0.0, 0.4 0.0, 0.2 0.1, 0.5 0.0, 0.4
≥75 (n=2,625) n 307 305 2 0 2 1
% 11.7 11.6 0.1 0 0.1 0.0
95% CI 10.5, 13.0 10.4, 12.9 0.0, 0.3 0.0, 0.1 0.0, 0.3 0.0, 0.2
Sex
Male (n=272) n 201 199 2 0 2 0
% 10.7 10.6 0.1 0 0.1 0
95% CI 9.4, 12.2 9.3, 12.1 0.0, 0.4 0.0, 0.2 0.0, 0.4 0.0, 0.2
Female (n=240) n 275 273 2 0 3 3
% 10.7 10.6 0.1 0 0.1 0.1
95% CI 9.5, 11.9 9.4, 11.8 0.0, 0.3 0.0, 0.1 0.0, 0.3 0.0, 0.3
DM, diabetes mellitus
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Retinopathy in patients with diabetes mellitus The overall
prevalence of retinopathy using HbA1c ≥6.5% for diagnosis
was 27.0% (95% CI 23.0, 31.0). The prevalence of DR in
the present study is lower than the 41% for any retinopathy
and 7% for PDR reported in 1994 in a previous study on
DR in Iceland [8]. This would also hold true if we used the
older classification of type 2 diabetes mellitus, which
includes fasting glucose ≥7 mml/l and would give an
overall prevalence of 25.3% in the present study, whereby
sex distribution in both studies is similar. However, the
previous study was based on clinical referrals and is
therefore likely to reflect selection bias. We attribute the
lower cholesterol to the use of lipid-lowering agents among
the group with type 2 diabetes.
The 25.3% overall prevalence of DR in AGES-R using
the older diagnostic criteria is similar to recent reports of:
(1) 24.8% in the Multi-Ethnic Study of Atherosclerosis
(MESA) in a white population with mean age of 64 years
[23]; and (2) the age- and sex-adjusted rate of 26.4% in
whites aged 40 years and older in the National Health and
Nutrition Examination Survey (NHANES) 2005–2008 [24],
the latter diagnosed using the HbA1c criteria.
The overall DR prevalence in the Beaver Dam Study in the
USA and the Blue Mountains Study in Australia was 36.8%
and 32.4%, respectively [25, 26]. These older studies,
however, used different definitions of type 2 diabetes
mellitus, including higher fasting serum glucose values than
our additional analysis, and therefore may have included
cases with more advanced disease than in the present study.
Differences in photographic techniques may also complicate
a direct comparison of the studies because the AGES-R and
MESA studies used digital non-stereoscopic 45° photographs
of two fields, while the Beaver Dam and the Blue Mountains
Eye studies used 30° stereoscopic photographs of up to
seven fields and might therefore have detected more
peripheral retinopathy lesions.
We confirmed findings from previous studies [23–30],
including a significant correlation between any DR in
persons with diabetes mellitus and insulin use, oral
hypoglycaemic medications, HbA1c ≥6.5% (≥48 mmol/mol)
and longer duration of diabetes mellitus. In agreement with
NHANES 2005–2008 [24], we found that higher systolic
blood pressure was associated with any DR in a multivariate
model. In a multivariate model, we found no correlation
between DR and BMI, hypertension or diastolic blood
pressure; this is in agreement with results from other studies
[23, 24, 26, 28]. Due to the extremely low prevalence of
PDR (1.0%; n=5) and CSMO (1.0%; n=5), statistical
analysis of associated factors was not attempted.
Retinopathy in non-diabetic persons We found a 10.7%
(n=476) prevalence of retinopathy in non-diabetic persons,
which is comparable to the 11.9% prevalence of retinopathy
reported in white non-diabetic persons in the MESA Study
[5]. In fact, although the prevalence of retinopathy in diabetic
patients is higher than in those without diabetes, the actual
number of individuals with retinopathy was threefold higher
in the non-diabetic group in our sample. Retinopathy lesions
among non-diabetic participants have been associated in
other studies with older age and hypertension [4, 6]. Non-
diabetic participants with signs of retinopathy in our study
were not more likely to be hypertensive, nor did they have
higher values of fasting serum glucose or HbA1c than those
without retinopathy. We did, however, find a strong
association between microalbuminuria and non-diabetic
retinopathy. While microalbuminuria has been confirmed to
be a reliable marker of retinopathy in diabetic patients [31],
we are not aware of previous data to confirm this relationship
in non-diabetic persons. Several studies [32, 33] have
suggested that since microvascular damage manifests outside
the eye in other organ systems, retinopathy and nephropathy
may share a common pathogenesis and be signs of systemic
microvascular dysfunction.
Patients who have been diagnosed with retinopathy in
eye clinics or screening programmes may want to know
how this affects management of their condition. Should
these elderly persons be referred for a diabetic work-up,
which commonly happens, or for a cardiovascular work-up,
or for both or neither? Interestingly, the Blue Mountains
Eye Study [5] describes most retinopathy lesions as being
transient, with only 3.5% of persons developing diabetes
over 5 years. We will need longitudinal data to further
understand the pathophysiology underlying retinopathy in
non-diabetic patients and to provide an evidence basis for
clinical management.
Study strengths and weaknesses A strength of the AGES-R
study is that the sample was drawn from a large, randomly
selected, population-based cohort. We also used a recently
recommended diagnosis criterion for diabetes mellitus,
namely HbA1c ≥6.5% (≥48 mmol/mol), thus avoiding
day-to-day variability of glucose values. HbA1c may be
better at predicting the development of retinopathy [34],
although this classification also has limitations [35]. This is
a multidisciplinary study, providing detailed information on
various physiological systems, including metabolic regula-
tion and ophthalmic health. The diabetes cases in our
sample included 83 individuals, i.e. 16.1% of the diabetes
mellitus sample, who were first diagnosed at the baseline
examination. All participants are survivors from the
Reykjavik study, which took place in several stages over a
30 year period from 1967 to 1997, with testing for diabetes
occurring at each examination, using the same fasting
serum glucose cut-off (≥7 mmol/l) as was used in our
additional analysis. Another strength of our study includes
the use of digital photographic documentation of each
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fundus through dilated pupils, as well as the masked
grading of retinopathy using standardised methods. Limi-
tations of this study include the relatively few cases of
diabetes mellitus and DR, resulting in reduced power to
detect factors associated with increased risk of retinopathy.
Summary This Icelandic population-based study reports
that more than one in seven elderly persons has retinopathy.
Although the prevalence of retinopathy among diabetic
patients is 2.5 times higher than among non-diabetic
persons, the actual number of individuals with retinopathy
is more than threefold higher in the non-diabetic group.
Retinopathy occurs in persons with HbA1c <6.5%
(≥48 mmol/mol) and also in persons with normal levels of
fasting serum glucose, and in these were significantly
associated with microalbuminuria in the present study.
Further study of the association between retinopathy and
microalbuminuria is needed to provide insight into under-
lying systemic disease processes, which could help in the
management of elderly patients to preserve vision and
health, and to maintain quality of life in old age.
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